NCT01439789 is a Phase 3 clinical trial of rhNRG-1 in Chronic Heart Failure, sponsored by Zensun Sci. & Tech. Co., Ltd..

Who is sponsoring NCT01439789?

NCT01439789 is sponsored by Zensun Sci. & Tech. Co., Ltd..

What drugs are being tested in NCT01439789?

Interventions in NCT01439789: rhNRG-1, Placebo.

What condition does NCT01439789 study?

NCT01439789 studies Chronic Heart Failure.

Is NCT01439789 still recruiting?

NCT01439789 is currently terminated. Last updated 19 December 2017.

Last reviewed 2017-12-19 · How we verify

NCT01439789

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure

Terminated Phase 3 Last updated 19 December 2017

What this trial tests

Phase 3 trial testing rhNRG-1 in Chronic Heart Failure in 146 participants. Terminated before completion.

Timeline

1 June 2011

Primary endpoint
1 June 2012

1 June 2012

Quick facts

Lead sponsor	Zensun Sci. & Tech. Co., Ltd.
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	146
Start date	1 June 2011
Primary completion	1 June 2012
Estimated completion	1 June 2012
Sites	21 locations across China

Drugs / interventions tested

rhNRG-1 — full drug profile →
Placebo

Conditions studied

Chronic Heart Failure — all drugs for Chronic Heart Failure →

Sponsor

Zensun Sci. & Tech. Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Chronic Heart Failure. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

NT-proBNP
Time frame: 30 days

Sponsor's own description

Multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on serum NT-proBNP, as well as safety in patients with chronic heart failure.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Neuregulin 1 Gene (<i>NRG1</i>). A Potentially New Targetable Alteration for the Treatment of Lung Cancer.
Rosas D, Raez LE, Russo A, Rolfo C. · · 2021 · cited 29× · PMID 34680187 · DOI 10.3390/cancers13205038
Neuregulin in Health and Disease.
Cespedes JC, Liu M, Harbuzariu A, Nti A, et al · · 2018 · cited 17× · PMID 31032468 · DOI 10.23937/2469-5866/1410024
Neuregulin-1 Administration Protocols Sufficient for Stimulating Cardiac Regeneration in Young Mice Do Not Induce Somatic, Organ, or Neoplastic Growth.
Ganapathy B, Nandhagopal N, Polizzotti BD, Bennett D, et al · · 2016 · cited 13× · PMID 27175488 · DOI 10.1371/journal.pone.0155456
Nanoscale piezoelectric patches preserve electrical integrity of infarcted hearts.
Monteiro LM, Gouveia PJ, Vasques-Nóvoa F, Rosa S, et al · · 2025 · cited 5× · PMID 40290879 · DOI 10.1016/j.mtbio.2025.101742

Verify or expand the search:

Other recruiting trials for Chronic Heart Failure

Currently open trials in the same condition.

NCT07265349 — A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure · Phase 1, PHASE2 · recruiting
NCT07379840 — A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South K · recruiting
NCT07325942 — Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure · NA · recruiting
NCT07434193 — Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergo · NA · recruiting
NCT07405944 — Vericiguat and Reverse Remodeling Indices in Heart Failure · Phase 4 · recruiting

Other Zensun Sci. & Tech. Co., Ltd. trials

Trials by the same sponsor.

NCT05949801 — Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients Wit · Phase 3 · completed
NCT04859621 — Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections · Phase 2 · unknown
NCT04468529 — Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01439789 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zensun Sci. & Tech. Co., Ltd.
Last refreshed: 19 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01439789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing